Tier 2 — strong

Effects of the flavonol quercetin and α-linolenic acid on n-3 PUFA status in metabolically healthy men and women: a randomised, double-blinded, placebo-controlled, crossover trial

Constanze Burak, Siegfried Wolffram, Berndt Zur, Peter Langguth, Rolf Fimmers, Birgit Alteheld, Peter Stehle, Sarah Egert
The British journal of nutrition 2017 117(5):698

Bibliography

PubMed
PMID 28366181
DOI
10.1017/S0007114517000241
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized double-blind placebo-controlled crossover nutrition trial
ModelHuman intervention research
Sample74 randomized adults; 67 analyzed
InterventionAlpha-linolenic acid about 3.6 g/day with quercetin 190 mg/day or placebo
Duration8-week periods with an 8-week washout
EndpointsSource-specific outcomes described in the key findings

What the study showed, in plain terms

Published in 2017, this source examined cardiovascular and metabolic health. Design: Randomized double-blind placebo-controlled crossover nutrition trial. Sample/model: 74 randomized adults; 67 analyzed. The exposure or intervention was Alpha-linolenic acid about 3.6 g/day with quercetin 190 mg/day or placebo. Follow-up or treatment period: 8-week periods with an 8-week washout.

ALA and EPA increased with both interventions. Quercetin did not add a favorable fatty-acid effect or improve DHA status.

Companion outcome report from an ALA-feeding program. Associations between flavonoid intake and fatty-acid status were not confirmed as a quercetin effect.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Weight Loss, Blood Sugar and Fatty Liver: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • ALA and EPA increased with both interventions.
  • Quercetin did not add a favorable fatty-acid effect or improve DHA status.
  • The recorded outcome domains were Source-specific outcomes described in the key findings.
  • The result applies to the tested exposure: Alpha-linolenic acid about 3.6 g/day with quercetin 190 mg/day or placebo; 8-week periods with an 8-week washout.

What this study can and cannot tell us

  • Companion outcome report from an ALA-feeding program. Associations between flavonoid intake and fatty-acid status were not confirmed as a quercetin effect.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Quercetins efficacy on bone and inflammatory markers, body composition, and physical function in postmenopausal women
Alyssa R Bailly et al. · Journal of bone and mineral metabolism · 2025
Tier 2
Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients
Pauline Mury et al. · Aging cell · 2025
Tier 2
Impact of quercetin in patients with myocardial infarction. A multicenter, randomized, and open-label pilot study
Sergey Kozhukhov et al. · Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese · 2024

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology